^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GC101 TIL

    i
    Other names: tumor infiltrating lymphocytes, GC101 TIL, autologous tumor infiltrating lymphocytes
    Associations

    News

    Trials
    Company:
    Gencells Therapeutics
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    10ms
    MIZAR-005: A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC (clinicaltrials.gov)
    P1, N=20, Recruiting, Shanghai Juncell Therapeutics | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial primary completion date
    |
    GC101 TIL
    10ms
    MIZAR: A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Shanghai Juncell Therapeutics | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • GC101 TIL
    11ms
    MIZAR-003: A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma (clinicaltrials.gov)
    P2, N=98, Recruiting, Shanghai Juncell Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • paclitaxel • Tyvyt (sintilimab) • temozolomide • dacarbazine • GC101 TIL
    1year
    MIZAR-003: Study Evaluating GC101 TIL (Autologous TIL) in the Treatment of Patients With Advanced Melanoma (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, Shanghai Juncell Therapeutics
    New P2 trial • Metastases
    |
    carboplatin • paclitaxel • Tyvyt (sintilimab) • temozolomide • GC101 TIL
    1year
    MIZAR-005: A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC (clinicaltrials.gov)
    P1, N=20, Recruiting, Shanghai Juncell Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GC101 TIL
    over1year
    MIZAR-005: A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Shanghai Juncell Therapeutics
    New P1 trial
    |
    GC101 TIL
    over1year
    Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial primary completion date • Metastases
    |
    cyclophosphamide • GC101 TIL
    over3years
    Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen. (PubMed, J Immunother Cancer)
    Omitting high dose of IL-2, she received intravenous dose of cyclophosphamide (20 mg/kg) for 3 days, approximately 48 hours before receiving the intravenous infusion of TILs. These results illustrated the potential value of modified lymphodepletion, followed by TILs for the treatment of patients with cervical cancer with local recurrence. Trial registration number, NCT04766320.
    Journal • Tumor-Infiltrating Lymphocyte
    |
    IL2 (Interleukin 2)
    |
    PD-1 expression
    |
    cyclophosphamide • GC101 TIL